NCT07138378View on ClinicalTrials.gov

A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions.

PHASE1CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

December 15, 2024

Study Completion Date

December 15, 2024

Conditions
Cancer
Interventions
DRUG

XS003 (nilotinib)

To evaluate the PK dose proportionality of Tasigna 200 mg versus Tasigna 400 mg and XS003 capsules 2x48mg (96mg) versus XS003 capsules 4x48mg (192mg).

DRUG

Tasigna (nilotinib)

To evaluate the PK dose proportionality of Tasigna 200 mg versus Tasigna 400 mg and XS003 capsules 2x48mg (96mg) versus XS003 capsules 4x48mg (192mg).

Trial Locations (1)

500037

QPS Bioserve India Pvt Limited, Hyderabad

All Listed Sponsors
lead

Xspray Pharma AB

INDUSTRY

NCT07138378 - A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions. | Biotech Hunter | Biotech Hunter